TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17558758
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel and LED treatments
Study: 15198839
Drug: Kenalog (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kenalog (triamcinolone acetonide) spray
Study: 15198839
Drug: Cortizone‐10 Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortizone‐10 Quick Shot (hydrocortisone) spray
Study: 15198839
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no corticosteroid spray)
Study: 11403522
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of scheduled naps and regular bedtimes
Study: 11403522
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stimulant medications alone)
Study: 8458044
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg twice a day
Study: 3023274
Drug: Nonselective beta-blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective beta-blockade (BB, 80 mg propranolol)
Study: 28057081
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV)
Study: 28057081
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg (RSV)
Study: 28057081
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg (FMS)
Study: 19697997
Drug: Mangosteen dietary
Normalized name: mangostin
DrugBank: Mangostin (DB14371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangosteen dietary supplement
Study: 11314678
Drug: MDMA (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (oral doses ranging from 70-150 mg, 1.35-1.8 mg/kg)
Study: 9398711
Drug: Iodine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine (0.2 mg/day)
Study: 8492053
Drug: Sensory Integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integration Treatment (SIT)
Study: 2379381
Drug: Oral ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketanserin 20mg (n = 14)
Study: 2379381
Drug: Oral ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketanserin 40mg (n = 8)
Study: 2379381
Drug: Intravenous ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin 5mg (n = 4)
Study: 4809462
Drug: 1 (2
Normalized name: RIBOCICLIB 200MG TAB,21 (200MG)DAILY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 (2 chloroethyl) 3 (4 methylcyclohexyl) 1 nitrosourea (methyl CCNU) at a dosage of 225 mg/sq m p.o. on day 1
Study: 4809462
Drug: Combination program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination program utilizing 5 fluorouracil, cyclophosphamide, and prednisone with or without vincristine
Study: 4809462
Drug: Cross over
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross over to methyl CCNU after initial treatment failure
Study: 4809462
Drug: Cross over
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross over to the combination program after initial treatment failure
Study: 4809462
Drug: Combination programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination programs
Study: 4809462
Drug: Vincristine (part
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (part of the combination program)
Study: 27723955
Drug: Salt room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt room with halogenerator (treatment group)
Study: 19192459
Drug: Combination lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination lithium carbonate/nortriptyline
Study: 18455084
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg/d
Study: 16649891
Drug: Radial shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial shock-wave therapy (RSWT)
Study: 16649891
Drug: Less active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less active similar therapy (Control)
Study: 7619662
Drug: L-365,260 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260 (10 mg, 50 mg p.o.)
Study: 2793453
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 mg every 8 hours)
Study: 25447269
Drug: Preservative-free fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% (once daily)
Study: 8371918
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% (twice daily)
Study: 25447269
Drug: Tafluprost 0.0015%
Normalized name: TAFLUPROST 0.0015% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafluprost 0.0015% (once daily)
Study: 25447269
Drug: Preservative-free fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5%
Study: 22114059
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (CT) applied once a week (G1)
Study: 22114059
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (CT) applied twice a week (G2)
Study: 17980977
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg sodium nitrate for 28 days
Study: 16354890
Drug: Progestin‐only pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin‐only pill
Study: 11942868
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen 2 mg/kg
Study: 11942868
Drug: Intramuscular ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ketoprofen 2 mg/kg
Study: 11942868
Drug: Placebo (intramuscular)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular)
Study: 11942868
Drug: Placebo (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (both intravenous and intramuscular)
Study: 9794747
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bendrofluazide daily
Study: 9794747
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bendrofluazide daily
Study: 9794747
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bendrofluazide every other day
Study: 876437
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of amoxycillin (3 g for adults and 100 mg/kg for children)
Study: 3887254
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of amoxycillin
Study: 6981162
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy
Study: 27782976
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) using oral magnesium citrate
Study: 25565485
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of fish oil (240 mg EPA + 240 mg DHA) with a multivitamin
Study: 25565485
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of fish oil (480 mg EPA + 480 mg DHA) with a multivitamin
Study: 25565485
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of fish oil without a multivitamin
Study: 23831445
Drug: Heparin-bonded covered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded covered stents (Viabahn)
Study: 21411235
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for comorbid SUD and PTSD
Study: 15334286
Drug: 10 microgrammes
Normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microgrammes recombinant hepatitis B vaccine
Study: 15334286
Drug: 20 microgrammes
Normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microgrammes recombinant hepatitis B vaccine
Study: 9710861
Drug: Optimal cut
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal cut point of 18.3 mL.kg-1.min-1
Study: 9710861
Drug: VO2 <
Normalized name: The full generic name for the drug abbreviation 'VO2 <' is not readily available. This abbreviation does not appear to be a standard drug name or abbreviation. It is more likely a measurement or parameter related to oxygen consumption or exercise physiology, rather than a specific drug. Without more context about the clinical trial data, I cannot provide the full generic name for this abbreviation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: VO2 < 18 mL.kg-1.min-1
Study: 1836989
Drug: 22 G
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 G spinal needle
Study: 1836989
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g iodine
Study: 24332248
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LD ASA)
Study: 24332248
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (HD ASA)
Study: 10231869
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of growth hormone (GH) and low-dose estrogen (ethinyl estradiol, 5 micrograms/d) in girls with Turner syndrome.
Study: 10231869
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) alone in girls with Turner syndrome.
Study: 10231869
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) alone in adults with Turner syndrome.
Study: 10231869
Drug: Estrogen (ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (ethinyl estradiol, 50 micrograms/d) and progesterone in combination with GH in adults.
Study: 9193221
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin and fluorouracil) plus radiation therapy
Study: 1493838
Drug: Nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 60 mg once daily
Study: 3554553
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg in 5 ml saline, repeated on demand)
Study: 3554553
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (10 mg on request)
Study: 30149366
Drug: nab‐paclitaxel, gemcitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab‐paclitaxel, gemcitabine, cisplatin and oral capecitabine (PAXG; arm A; N = 26)
Study: 22582765
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral therapy (I-CBT)
Study: 17545008
Drug: Novel immunosuppressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel immunosuppressive agents and established immunosuppressive agents
Study: 17545008
Drug: Newer immunosuppressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer immunosuppressive agents (proliferation signal inhibitors)
Study: 17545008
Drug: Costimulatory pathway
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costimulatory pathway inhibitors and other new immunosuppressive agents
Study: 16213136
Drug: Intravaginal micronised
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal micronised progesterone 200 mg three times daily (n=351)
Study: 16213136
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 10 mg twice daily (n=79)
Study: 8536446
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 50 micrograms/norethindrone 1 mg
Study: 8536446
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 35 micrograms/norethindrone 1 mg
Study: 8536446
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 35 micrograms/norethindrone 0.5 mg
Study: 28027641
Drug: Wolfberry Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wolfberry Extract (WBE) - 13.5 g in 80 mL pouch, consumed after one meal per day for 8 weeks
Study: 23570290
Drug: DSL v5
Normalized name: Immunitor V5
DrugBank: Tubimod (DB17745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSL v5 prescription
Study: 23570290
Drug: NAL‐NL1 prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAL‐NL1 prescription
Study: 22122291
Drug: Cue exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue exposure treatment-food
Study: 18210717
Drug: Fixed drug
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed drug combination RMP300 HIN150 (20 patients)
Study: 18210717
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug tablets (RMP and HIN) (18 patients)
Study: 18210717
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (20 patients with fixed drug combination and 18 patients with single drug tablets)
Study: 7803946
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (specifics not detailed, but mentions diuretics and beta-adrenergic blocking drugs)
Study: 7803946
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (ACE inhibitors and calcium channel blockers)
Study: 2468858
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg (acute oral administration)
Study: 2468858
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg b.i.d. (chronic oral administration)
Study: 28063325
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo NRT sampling (patch, gum, combination NRT)
Study: 25051390
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (3 mg·kg of caffeine)
Study: 23541416
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (ganirelix 0.25mg daily)
Study: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, low dose (2.5/80 mg, titrated to 5/160 mg or 10/160 mg)
Study: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, high dose (5/80 mg, titrated to 5/160 mg or 10/160 mg)
Study: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy with optional hydrochlorothiazide (HCTZ) 12.5 mg
Study: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, low dose
Study: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, high dose
Study: 18156922
Drug: Intra-arterial iodine-131-labeled
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial iodine-131-labeled lipiodol (1850 MBq dose)
Study: 12911824
Drug: Serrapeptase (SER)
DrugBank: Serrapeptase (DB13131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serrapeptase (SER) 30 mg/day for 4 weeks
Study: 7421183
Drug: Biofeedback-relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-relaxation therapy (30 1-hour training sessions over a 13-week period)
Study: 7421183
Drug: Biofeedback-relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-relaxation therapy (after 3 months of control)
Study: 7421183
Drug: Biofeedback-relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-relaxation therapy
Study: 31430226
Drug: Pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib (400 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Study: 31430226
Drug: Lapatinib (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,250 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Study: 23448616
Drug: Ticagrelor (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (450 mg single dose, 180 mg 12 hours later, twice daily for 2 days, and once on day 4)
Study: 15169685
Drug: NK(3) antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK(3) antagonist (SR142801)
Study: 15169685
Drug: 5‐HT(2A/2C) antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT(2A/2C) antagonist (SR46349B)
Study: 15169685
Drug: CB(1) antagonist
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB(1) antagonist (SR141716)
Study: 15169685
Drug: NTS(1) antagonist
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTS(1) antagonist (SR48692)
Study: 1201184
Drug: Potassium supplements
Normalized name: POTASSIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplements
Study: 1201184
Drug: Prednisone (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (without potassium supplements)
Study: 26149441
Drug: Kokoro-App plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kokoro-App plus switching antidepressant
Study: 26149441
Drug: Switching antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching antidepressant alone
Study: 21275440
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 60 mg XR
Study: 19738015
Drug: Boost Plus
Normalized name: Boost Plus Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost Plus 8 oz (240 ml)
Study: 19738015
Drug: Boost Plus
Normalized name: Boost Plus Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost Plus 4 oz (120 ml)
Study: 19738015
Drug: Boost Plus
Normalized name: Boost Plus Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost Plus 2 oz (60 ml)
Study: 19738015
Drug: Boost Plus
Normalized name: Boost Plus Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost Plus 1 oz (30 ml)
Study: 17803714
Drug: Misoprostol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (600 micrograms oral)
Study: 15167287
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg
Study: 15167287
Drug: Atazanavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 600 mg
Study: 15167287
Drug: Nelfinavir-to-atazanavir switch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir-to-atazanavir switch (400 mg)
Study: 9514180
Drug: Cicletanine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (50 mg daily, orally)
Study: 7995312
Drug: Hydrochlorothiazide added
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide added to Lisinopril
Study: 26751191
Drug: NBI-77860 300
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-77860 300 mg
Study: 26751191
Drug: NBI-77860 600
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-77860 600 mg
Study: 17616002
Drug: CCGC (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCGC (combined capsaicin, green tea extract, and chicken essence tablets)
Study: 16095444
Drug: Epidural lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lidocaine (2% lidocaine, 15 ml, maintenance infusion rate of 6 ml h‐1)
Study: 16095444
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone (normal saline, 15 ml, maintenance infusion rate of 6 ml h‐1)
Study: 9862538
Drug: Phenol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenol (3 ml of 5% phenol via tibial nerve blockade)
Study: 2576432
Drug: 1% D-timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% D-timolol (topical administration)
Study: 27719741
Drug: GSK2647544 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2647544 (0.5 - 750 mg single escalating oral doses)
Study: 27719741
Drug: GSK2647544 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2647544 (80 mg repeat doses)
Study: 23455596
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg) with water
Study: 23455596
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg) with yoghurt-based drink
Study: 23455596
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg) with glucose-based drink
Study: 23455596
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg) irrespective of vehicle
Study: 16963034
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release metformin
Study: 10939702
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen 400 mg